Dolorin Junior Endaþarmsstíll 125 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

dolorin junior endaþarmsstíll 125 mg

williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 125 mg

Dolorin Junior Endaþarmsstíll 250 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

dolorin junior endaþarmsstíll 250 mg

williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 250 mg

Dolorin Junior Mixtúra, lausn 24 mg/ml איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

dolorin junior mixtúra, lausn 24 mg/ml

williams & halls ehf. - paracetamolum inn - mixtúra, lausn - 24 mg/ml

Sandostatin Stungulyf, lausn 100 míkróg/ml איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin stungulyf, lausn 100 míkróg/ml

novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 100 míkróg/ml

Sandostatin Stungulyf, lausn 50 míkróg/ml איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin stungulyf, lausn 50 míkróg/ml

novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 50 míkróg/ml

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 10 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 20 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 20 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 20 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 30 mg איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 30 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 30 mg

Hemangiol האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

hemangiol

pierre fabre medicament - própranólól hýdróklóríð - hemangioma - betablokkar - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Tivicay האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

tivicay

viiv healthcare bv - dolutegravír - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.